As per the research report, the size of the Europe Glycobiology Market is valued at USD 233.22 million in 2019 and estimated to be growing at a CAGR of 13.4%, to reach USD 437.35 million by 2024 during the forecast period 2019-2024.
The market is showcasing evident potential in the mentioned forecasting period. The market continues to gain momentum with rapid development in the medical industry.
Glycobiology is the study of the structure, function, and biology of carbohydrates, also known as glycans, which are distributed in nature. It is a tiny but quickly growing field in biology, with importance to biomedicine, biotechnology, and basic research.
Advancements in glycomics instruments technology are expected to be a major factor in driving the market growth. Moreover, growing investments in research & development by the government along with the rising focus of pharmaceutical and biotechnology companies on novel drug development are the major factors that are driving the growth of the Glycobiology market.
This research report segmented and sub-segmented into the following categories:
The Europe Glycobiology Market is expected to show significant growth in the forecast period due to the growing focus on R & D.
Key players operating in the Europe Glycobiology Market profiled in this report are Agilent Technologies (U.S.), Bruker Corporation (U.S.), Danaher Corporation (U.S.), New England Biolabs (U.S.), ProZyme, Inc. (U.S.), Shimadzu Corporation (Japan), Merck KGaA (Germany), Takara Bio, Inc. (Japan), Thermo Fisher Scientific (U.S.), and Waters Corporation (U.S.).,
1. Introduction
1.1 Market Definition
1.2 Study Deliverables
1.3 Base Currency, Base Year and Forecast Periods
1.4 General Study Assumptions
2. Research Methodology
2.1 Introduction
2.2 Research Phases
2.2.1 Secondary Research
2.2.2 Primary Research
2.2.3 Econometric Modelling
2.2.4 Expert Validation
2.3 Analysis Design
2.4 Study Timeline
3. Overview
3.1 Executive Summary
3.2 Key Inferences
3.3 Epidemology
4. Drivers, Restraints, Opportunities, and Challenges Analysis (DROC)
4.1 Market Drivers
4.2 Market Restraints
4.3 Key Challenges
4.4 Current Opportunities in the Market
5. Market Segmentation
5.1 Product
5.1.1 Introduction
5.1.2 Enzymes
5.1.3 Instruments
5.1.4 Kits & Reagents
5.1.5 Y-o-Y Growth Analysis, By Product
5.1.6 Market Attractiveness Analysis, By Product
5.1.7 Market Share Analysis, By Product
5.2 Application
5.2.1 Introduction
5.2.2 Diagnostic
5.2.3 Drug Discovery
5.2.4 Oncology
5.2.5 Y-o-Y Growth Analysis, By Application
5.2.6 Market Attractiveness Analysis, By Application
5.2.7 Market Share Analysis, By Application
5.3 Instruments
5.3.1 Introduction
5.3.2 HPLS
5.3.3 Mass Spectrometry
5.3.4 MALDITOF
5.3.5 Y-o-Y Growth Analysis, By Instruments
5.3.6 Market Attractiveness Analysis, By Instruments
5.3.7 Market Share Analysis, By Instruments
5.4 End User
5.4.1 Introduction
5.4.2 Academic research institutes
5.4.3 pharmaceutical & biotechnology companies
5.4.4 contract research organizations
5.4.5 Y-o-Y Growth Analysis, By End User
5.4.6 Market Attractiveness Analysis, By End User
5.4.7 Market Share Analysis, By End User
6. Geographical Analysis
6.1 Introduction
6.1.1 Regional Trends
6.1.2 Impact Analysis
6.1.3 Y-o-Y Growth Analysis
6.1.3.1 By Geographical Area
6.1.3.2 By Product
6.1.3.3 By Application
6.1.3.4.By Instruments
6.1.3.5 By End User
6.1.4 Market Attractiveness Analysis
6.1.4.1 By Geographical Area
6.1.4.2 By Product
6.1.4.3 By Application
6.1.4.4.By Instruments
6.1.4.5 By End User
6.1.5 Market Share Analysis
6.1.5.1 By Geographical Area
6.1.5.2 By Product
6.1.5.3 By Application
6.1.5.4.By Instruments
6.1.5.5 By End User
6.2 U.K
6.3 Spain
6.4 Germany
6.5 Italy
6.6 France
7. Strategic Analysis
7.1 PESTLE analysis
7.1.1 Political
7.1.2 Economic
7.1.3 Social
7.1.4 Technological
7.1.5 Legal
7.1.6 Environmental
7.2 Porter’s Five analysis
7.2.1 Bargaining Power of Suppliers
7.2.2 Bargaining Power of Consumers
7.2.3 Threat of New Entrants
7.2.4 Threat of Substitute Products and Services
7.2.5 Competitive Rivalry within the Industry
8. Market Leaders' Analysis
8.1 Agilent Technologies
8.1.1 Overview
8.1.2 Product Analysis
8.1.3 Financial analysis
8.1.4 Recent Developments
8.1.5 SWOT analysis
8.1.6 Analyst View
8.2 Bruker Corporation
8.3 Danaher Corporation
8.4 New England Biolabs
8.5 ProZyme, Inc.
8.6 Shimadzu Corporation
8.7 Merck KGaA
8.8 Takara Bio, Inc.
9. Competitive Landscape
9.1 Market share analysis
9.2 Merger and Acquisition Analysis
9.3 Agreements, collaborations and Joint Ventures
9.4 New Product Launches
10. Market Outlook and Investment Opportunities
Appendix
a) List of Tables
b) List of Figures
Related Reports
